Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021

Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has announced that its Chairman, Gabriele Cerrone, will appear on Bloomberg Television on March 30, 2021, at 1:50 PM US Eastern Time. This update corrects the previously announced schedule. Tiziana focuses on developing innovative therapies for oncology and inflammation, including Milciclib and Foralumab, the latter being a fully human anti-CD3 monoclonal antibody for various autoimmune and inflammatory diseases. The company is also advancing an anti-IL6R monoclonal antibody for treating COVID-19 related inflammation.

Positive

• Development of Foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development.
• Potential applications of Foralumab in multiple autoimmune and inflammatory diseases, increasing its market relevance.
• Accelerated development of anti-IL6R monoclonal antibody for COVID-19 treatment, addressing a critical healthcare need.

Negative

• None.

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, clarifies that its Chairman and Founder, Gabriele Cerrone, will be giving an interview on Bloomberg Television on Tuesday, 30 March 2021 at 1.50 p.m. US Eastern Standard Time (6.50 p.m. London) as part of the Bloomberg Markets Show.

This is an amendment to the previous time and date communicated.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc (TLSA)

Gabriele Cerrone, Chairman, and founder

+44 (0)20 7495 2379

U.S. Investor Relations Contact:

RedChip Companies, Inc.

Dave Gentry

1-800 RED-CHIP (733-2447)

Or 407-491-4498

Dave@redchip.com

FAQ

What is the purpose of Gabriele Cerrone's interview on Bloomberg Television?

Gabriele Cerrone's interview aims to provide insights on Tiziana Life Sciences' advancements and initiatives.

When is Gabriele Cerrone scheduled to appear on Bloomberg Television?

He is scheduled to appear on March 30, 2021, at 1:50 PM US Eastern Time.

What are the key products being developed by Tiziana Life Sciences?

Key products include Milciclib and Foralumab, targeting various diseases, including autoimmune and inflammatory conditions.

What is Foralumab and its significance?

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, indicating its unique position in the market.

How is Tiziana Life Sciences addressing COVID-19?

The company is developing an anti-IL6R monoclonal antibody specifically for treating inflammation in COVID-19 patients.